Biogated mesoporous silica nanoagents for inhibition of cell migration and combined cancer therapy

• Published in: Mikrochimica acta (1966) Vol. 191; no. 6; p. 326
• Main Authors: Wu, Yu, Shi, Xiao-Jie, Dai, Xin-Yi, Song, Tian Shun, Li, Xiang-Ling, Xie, Jing Jing
• Format: Journal Article
• Language: English
• Published: Vienna Springer Vienna 01.06.2024; Springer; Springer Nature B.V
• Subjects: A549 Cells; Analytical Chemistry; Antimitotic agents; Antineoplastic agents; Cancer; Cancer therapies; Care and treatment; Cell Movement - drug effects; Characterization and Evaluation of Materials; Chemistry; Chemistry and Materials Science; Drug delivery systems; Drug Therapy, Combination - methods; Drugs; Gene therapy; Health aspects; Humans; Lung cancer; Lung cancer, Non-small cell; Metastasis; Microengineering; MicroRNA; Microscopy, Electron, Transmission; Nanochemistry; Nanoparticle Drug Delivery System - chemistry; Nanoparticle Drug Delivery System - therapeutic use; Nanoparticles - chemistry; Nanoparticles - therapeutic use; Nanoparticles - ultrastructure; Nanotechnology; Neoplasms - drug therapy; Oligonucleotides; Original Paper; Prevention; Silica; Silicon dioxide; Silicon Dioxide - chemistry; Tumors; Vehicles; miR-330-3p; Migratory inhibition; Biogate; MSNs; Synergistic therapy
• ISSN: 0026-3672; 1436-5073; 1436-5073
• DOI: 10.1007/s00604-024-06401-5

Migration is an initial step in tumor expansion and metastasis; suppressing cellular migration is beneficial to cancer therapy. Herein, we designed a novel biogated nanoagents that integrated the migration inhibitory factor into the mesoporous silica nanoparticle (MSN) drug delivery nanosystem to realize cell migratory inhibition and synergistic treatment. Antisense oligonucleotides (Anti) of microRNA-330-3p, which is positively related with cancer cell proliferation, migration, invasion, and angiogenesis, not only acted as the locker for blocking drugs but also acted as the inhibitory factor for suppressing migration via gene therapy. Synergistic with gene therapy, the biogated nanoagents (termed as MSNs-Gef-Anti) could achieve on-demand drug release based on the intracellular stimulus-recognition and effectively kill tumor cells. Experimental results synchronously demonstrated that the migration suppression ability of MSNs-Gef-Anti nanoagents (nearly 30%) significantly contributed to cancer therapy, and the lethality rate of the non-small-cell lung cancer was up to 70%. This strategy opens avenues for realizing efficacious cancer therapy and should provide an innovative way for pursuing the rational design of advanced nano-therapeutic platforms with the combination of cancer cell migratory inhibition. Graphical abstract